Dronedarone News and Research

RSS

Dronedarone (also known as Multaq) is a drug used mainly for the indication of cardiac arrhythmias (irregular heartbeat).

Scientists develop an improved pharmaceutical drug for the treatment of atrial fibrillation

Scientists from the National University of Singapore Department of Pharmacy have developed an improved pharmaceutical drug for the treatment of the most common heart rhythm disturbance – atrial fibrillation (AF).

18 Jul 2022

Study identifies a host of agents with anti-SARS-CoV-2 potential

A team of researchers at the Genomics Research Center, Academia Sinica, in Taiwan, evaluated the efficacy of 2,855 agents against SARS-CoV-2.

22 Jan 2021

Three FDA-approved drugs can block the replication of COVID-19 virus

Three drugs that are already approved by the Food and Drug Administration (FDA) or other international agencies can block the production of the novel coronavirus that causes COVID-19 in human cells, according to computational and pharmaceutical studies performed by UT Southwestern scientists.

19 May 2020

Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration granted approval of Praxbind (idarucizumab). PRAXBIND is indicated for patients treated with Pradaxa (dabigatran etexilate mesylate), when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.

16 Oct 2015

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE).

8 Apr 2014

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital, an internationally recognized teaching affiliate of Harvard Medical School known for its excellence in patient care, medical research and training of outstanding young health professionals.

17 Aug 2013

Dabigatran decreases risk of recurrent venous thromboembolism

New findings from two double-blind, randomized trials, RE-MEDY and RE-SONATE, show that dabigatran 150 mg twice daily reduces the risk of recurrent venous thromboembolism (VTE).

21 Feb 2013

Updated U.S. prescribing information for Boehringer Ingelheim’s Pradaxa

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. prescribing information for Pradaxa (dabigatran etexilate mesylate) capsules was updated to include a contraindication related to use in patients with mechanical prosthetic heart valve replacement.

21 Dec 2012

Pradaxa use does not appear to increase serious bleeding

The U.S. Food and Drug Administration (FDA) today announced the results of a Mini-Sentinel assessment that indicates bleeding rates associated with new use of Pradaxa (dabigatran etexilate mesylate) capsules do not appear to be higher than bleeding rates associated with new use of warfarin, which is consistent with observations from the pivotal RE-LY trial.

4 Nov 2012

Study supports catheter ablation as first-line treatment for paroxysmal atrial fibrillation

Patients with the heart rhythm disorder atrial fibrillation (AFib) who received first-line catheter ablation treatment had a longer arrhythmia-free interval than patients receiving antiarrhythmic drugs, the standard first-line treatment.

11 May 2012

One in three AF patients at high risk of stroke are not being prescribed VKA therapy

New data show that, worldwide, one in three patients with atrial fibrillation (AF) who are at high risk for stroke are not being prescribed anticoagulant therapy, particularly vitamin K antagonists (VKA) – medicines known to significantly lower stroke risk in these patients.

29 Aug 2011

ESC to produce focused update on AF Guidelines following early termination of PALLAS Trial

The Guidelines Department of the European Society of Cardiology has issued the following statement today: "The European Society of Cardiology (ESC) is aware of the early termination of the PALLAS trial because of adverse outcomes associated with dronedarone.

5 Aug 2011

Lead investigator to discuss growing impact of AFib on US health care costs and resources

Two studies to be presented this week address the often-overlooked costs associated with atrial fibrillation, the most common form of cardiac arrhythmia.

5 May 2011

CCS presents new 2010 Atrial Fibrillation Guidelines

The Canadian Cardiovascular Society (CCS) presented its new 2010 Atrial Fibrillation Guidelines, the first update in six years, at the Canadian Cardiovascular Congress (CCC) in Montreal.

28 Oct 2010

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Sanofi-aventis announced today the initiation of a multinational, randomized double-blind Phase IIIb trial, PALLAS, to assess the potential clinical benefit of Multaq(R) (dronedarone) in over 10, 000 patients with permanent atrial fibrillation (AF) to reduce major adverse cardiovascular events. The announcement was made during Heart Rhythm 2010, the Heart Rhythm Society's 31st Annual Scientific Sessions.

12 May 2010

Antiarrhythmic drug dronedarone less effective and causes fewer side effects

In a rigorous new review of the antiarrhythmic drug dronedarone (Multaq), researchers at the Cedars-Sinai Heart Institute conclude that the controversial drug is only modestly effective and has no clear safety benefits.

6 Apr 2010

NICE appraisal committee publishes preliminary recommendation of Multaq for AF

Sanofi-aventis announced today that the National Institute for Health and Clinical Excellence (NICE) in England and Wales, has just published a new appraisal consultation document for Multaq(R) (dronedarone) indicating its intention to recommend Multaq(R) use for the management of patients with atrial fibrillation.

30 Mar 2010

Physician scientists present new findings on aspirin therapy, atrial fibrillation drug therapy and LVAD

Physician scientists from the Cedars-Sinai Heart Institute presented new findings on the effectiveness of routine aspirin therapy for preventing heart disease, a drug therapy for atrial fibrillation and the role left ventricular assist devices may play in weight reduction for obese patients with chronic end-stage heart failure who are considered for heart transplantation.

19 Mar 2010

Decision Resources: Atrial fibrillation drug market to increase more than sevenfold

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to the launches of several new agents, the atrial fibrillation drug market will increase more than sevenfold from $790 million in 2008 to $6.1 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

15 Dec 2009

European CHMP recommends marketing approval for Sanofi-aventis' Multaq

Sanofi-aventis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending to grant a marketing authorization in the European Union for Multaq(R) (dronedarone - 400mg Tablets).

26 Sep 2009